Exane Derivatives Viking Therapeutics, Inc. Transaction History

Exane Derivatives

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$2.11 - $3.15 $58,607 - $87,494	-27,776 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$3.0 - $4.88 $83,328 - $135,546	27,776 New	27,776 $83,000
Q4 2021 Jan 28, 2022	SELL	$4.6 - $6.72 $138,667 - $202,574	-30,145 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$5.58 - $7.04 $34,439 - $43,450	6,172 Added 25.75%	30,145 $189,000
Q2 2021 Jul 28, 2021	SELL	$5.19 - $6.73 $109,555 - $142,063	-21,109 Reduced 46.82%	23,973 $143,000
Q1 2021 Apr 30, 2021	SELL	$5.74 - $9.67 $35,599 - $59,973	-6,202 Reduced 12.09%	45,082 $285,000
Q4 2020 Jan 27, 2021	BUY	$5.3 - $6.71 $33,957 - $42,990	6,407 Added 14.28%	51,284 $288,000
Q3 2020 Oct 08, 2020	BUY	$5.73 - $8.11 $257,145 - $363,952	44,877 New	44,877 $261,000
Q3 2020 Oct 06, 2020	SELL	$5.73 - $8.11 $251,392 - $355,810	-43,873 Closed	0 $0
Q2 2020 Jul 10, 2020	SELL	$4.35 - $8.08 $40,459 - $75,152	-9,301 Reduced 17.49%	43,873 $316,000
Q1 2020 Apr 17, 2020	BUY	$3.45 - $7.95 $183,450 - $422,733	53,174 New	53,174 $248,000

466

63.8M

5.76M

3.4M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.6B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.